All In Biotech

Drug Trial Radar · NCT05282953

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Nov 10, 2022

Primary completion

Aug 10, 2023

Study completion Mar 24, 2026

Sponsor

Lead sponsor
Kiora Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia (ABACUS).

Conditions

  • Retinitis Pigmentosa
  • Choroideremia
  • Non-Syndromic Rod-Dominant Inherited Retinal Diseases

Interventions

  • KIO-301Drug

    KIO-301 intravitreal injection at ascending doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Study Primary Outcome MeasureTime frame: 84 days.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Save Sight Institute

    Sydney, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Harley Eye Clinic

    North Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.